Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
Nature. 2018 Jun;558(7711):540-546. doi: 10.1038/s41586-018-0217-9. Epub 2018 Jun 13.
Nature. 2018.
PMID: 29899452
Free PMC article.
Clinical Trial.
Clinical and genetic analyses of patients with lateralized overgrowth.
Kim YM, Lee Y, Choi Y, Choi IH, Heo SH, Choi JM, Do HS, Jang JH, Yum MS, Yoo HW, Lee BH.
Kim YM, et al.
BMC Med Genomics. 2022 Sep 30;15(1):206. doi: 10.1186/s12920-022-01362-1.
BMC Med Genomics. 2022.
PMID: 36175890
Free PMC article.
METHODS: Fifteen patients with lateralized overgrowth were involved. Clinical characteristics and whole-body magnetic resonance imaging (WB-MRI) findings were evaluated. ...Propranolol could be applied as an adjuvant therapy for reducing vascular symptoms, but a PIK3CA inh …
METHODS: Fifteen patients with lateralized overgrowth were involved. Clinical characteristics and whole-body magnetic resonance imagi …
Item in Clipboard
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Garreta Fontelles G, Pardo Pastor J, Grande Moreillo C.
Garreta Fontelles G, et al.
Br J Clin Pharmacol. 2022 Aug;88(8):3891-3895. doi: 10.1111/bcp.15270. Epub 2022 Feb 21.
Br J Clin Pharmacol. 2022.
PMID: 35146800
Free article.
CLOVES syndrome is a rare congenital overgrowth disorder caused by mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene. It is part of the PIK3CA-related overgrowth syndrome (PROS) spectrum and its treatment is challengi …
CLOVES syndrome is a rare congenital overgrowth disorder caused by mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (P …
Item in Clipboard
Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
Forde K, Resta N, Ranieri C, Rea D, Kubassova O, Hinton M, Andrews KA, Semple R, Irvine AD, Dvorakova V.
Forde K, et al.
Orphanet J Rare Dis. 2021 Feb 27;16(1):109. doi: 10.1186/s13023-021-01745-0.
Orphanet J Rare Dis. 2021.
PMID: 33639990
Free PMC article.
Clinical Trial.
CONCLUSION: We report the first paediatric case series of the use of miransertib in two children with PROS. Objective clinical response was observed in patient one, and improvement in key qualitative outcomes was reported in patient two. ...
CONCLUSION: We report the first paediatric case series of the use of miransertib in two children with PROS. Objective clinical respon …
Item in Clipboard
Cite
Cite